In line with these results, other publications have already registered a rise in Bcl-XL expression after DCA incubation in several tumor types, such as lung adenocarcinoma, colorectal cancer [25] and oral squamous cell carcinoma [43], and, still, that did not stop the therapies from working. This evidence concerns the gene BCL2L1 and lung adenocarcinoma.